Delivery Order SPE2DB20D2104-SPE2DB24FMASD
- Not listed
- This federal contract award, valued at $1,639.70, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of LIVALO 4 MG TABLET 90S, a pharmaceutical product. The contract is a Delivery Order with a Firm Fixed Price pricing type and has a completion date of December 20, 2023. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award, valued at $1,763.44, was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of LIVALO 2 MG TABLET 90S, a pharmaceutical product, to support military healthcare programs. The contract has an ultimate completion date of June 27, 2024 and is a Firm Fixed Price Delivery Order. The contract is not associated with a set-aside designation,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,219.94 firm fixed-price delivery order is for the supply of 90 tablets of the prescription medication LIVALO 2 MG. The contract has an ultimate completion date of July 2, 2025 and is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC)...
- This federal contract award, valued at $89,529.53, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for Amerisourcebergen to provide a comprehensive...
- This federal contract award, valued at $2,990.95, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of LIVALO 4 MG TABLET 90S, a pharmaceutical product, and has an ultimate completion date of November 1, 2024. The contract is a Delivery Order with a Firm Fixed Price pricing type. This award is not designated as a set-aside contract. AmerisourceBergen Drug Corp...
- This federal contract award, with ID SPE2DX15D3020|SPE2DX23FXHLN, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor, Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $11,185.76 firm-fixed-price delivery order is for the supply of the pharmaceutical product LIVALO 2 MG TABLET 90S. The contract has an ultimate completion date of August 8, 2023. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract...
- This federal contract award, valued at $1,363.82, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of LIVALO 4 MG TABLET 90S, a pharmaceutical product, with a completion date of July 15, 2024. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at $999,999,999 and...
- This federal contract award, valued at $17,208.45, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The contract provides for the delivery of LIVALO 4 MG TABLET 90S, a pharmaceutical product, with a performance period ending on May 10, 2023. The contract has no set-aside...
- This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for the delivery of pharmaceutical products, including the drug Livalo 1 mg tablet. The contract has a ceiling value of $1,351.28 and runs through February 7, 2024. It is a firm fixed-price delivery order contract with no set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA...
- This is a federal contract award issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,146.26, is for the delivery of LIVALO 2 MG TABLET 90S, a pharmaceutical product. The contract has a firm fixed price and an ultimate completion date of November 15, 2023. This award is not designated as a set-aside contract. Amerisourcebergen Drug Corp holds a...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB24FMASDDelivery Order
This federal contract award is a Delivery Order (DO) valued at $2,511.90, issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp. The contract is for the delivery of LIVALO 1 MG TABLET 90S, a pharmaceutical product, with a completion date of September 4, 2024. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that has established itself as a key vendor for federal healthcare programs, particularly within military and veterans' healthcare systems. The company holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. Additionally, Amerisourcebergen maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. The contract award does not have a set-aside designation, indicating open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.5k | 9/3/24 |